



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

1
2 **ADMINISTRATIVE ORDER**

3 No. 2023- _____
4
5

6 **SUBJECT: Implementing Guidelines on the Schedule of Fees and Charges of**
7 **the Food and Drug Administration for Licensing, Registration**
8 **and Other Authorizations and Regulatory Services Repealing**
9 **Administrative Order No. 50s. 2001, entitled, "Revised 2001**
10 **Schedule of Fees and Charges for the Corresponding Services**
11 **Rendered by the Bureau of Food and Drugs" and its Amendments**
12
13

14 **I. RATIONALE**
15

16 The Food and Drug Administration (FDA) is mandated by Republic Act No. 9711 also
17 known as the "Food and Drug Administration Act of 2009", to license all the establishments or
18 facilities and issue product market authorization on all health products prior to manufacture,
19 importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use,
20 promotion, advertising, or sponsorship. Accordingly, to protect public health and uphold
21 consumer safety, the FDA conducts post-market surveillance of health products and
22 establishments or facilities to ensure that adulterated, unregistered, or misbranded health
23 products are not offered for sale or use.
24

25 Pursuant to Article II A. Section 2.s. of the Implementing Rules and Regulations of the
26 Republic Act (RA) No. 9711, the FDA is authorized to review its fees periodically and propose
27 any increase and promulgate rules and regulations governing the collection of other related
28 regulatory fees. Accordingly, under Article II B. Section 3 of the said Act, the FDA is
29 authorized to collect, retain, and utilize or apply all fees, fines, royalties, and other charges
30 collected by it under Section 31 of the Republic Act No. 9502 also known as the "Universally
31 Accessible Cheaper and Quality Medicines Act of 2008" which includes upgrading of its
32 facilities, equipment outlay, human resource development, and expansion; acquisition of the
33 appropriate office space, as well as purchases of laboratory equipment and motor vehicles;
34 upgrading of its current facilities and equipment and maintenance; funding for operating
35 expenses of the central office laboratory divisions and satellite laboratories; and other activities
36 or services of the FDA in the performance of its mandate
37

38 With the current innovations in technology and the improvement of the country's
39 economy evidenced by the flourishing volume of industries in health products, a commensurate
40 increase in the fees and charges is considerably needed to be able to meet and sustain the
41 increasing demands of providing the FDA stakeholders quality and efficient services. For more
42 than twenty (20) years, the rate of fees and charges of the Food and Drug Administration has
43 been referred to the Administrative Order No. 50 s.2001 or the Revised 2001 Schedule of Fees
44 and Charges for the Corresponding Services Rendered by the Bureau of Food and Drugs. Thus,
45 in view of the foregoing, a revisit and consequent repeal of Administrative Order No. 50 s. 2001
46 is deemed in order.
47

48 In the interest of the service and pursuant to the DOF-DBM-NEDA Joint Circular No.
49 1-2013, also known as the “Implementing Rules and Regulations of Administrative Order No.
50 31 s. 2012 on the Rationalization of Rates of Fees and Charges, Increase in Existing Rates and
51 Imposition of New Fees and Charges”, the FDA is restructuring its fees and charges at a level
52 commensurate with the cost of regulating health products, establishments or facilities to protect
53 consumer safety and public health. Thus, the following guidelines are hereby adopted.
54

55 **II. OBJECTIVE**

56
57 This Administrative Order is issued to prescribe the schedule of fees and charges for
58 the services rendered by the FDA and provide the guidelines for its implementation.
59

60
61 **III. SCOPE**

62
63 The new schedule of fees and charges shall apply to all persons, establishments or
64 facilities and health products under FDA’s jurisdiction whether public or private, including but
65 not limited to national and local government agencies, state colleges and universities, and
66 schools, availing of FDA’s services.
67

68
69 **IV. DEFINITION OF TERMS**

70
71 For the purpose of implementing this Order, all terms used in this Order that are
72 already defined in RA No. 3720 as amended by EO No. 175 and RA No. 9711 shall have the
73 same meaning as defined therein. For emphasis, the following terms shall be defined as follows:
74

- 75 A. **Accreditation** refers to the attestation conveying a formal demonstration of a
76 laboratory's competence and capability to carry out specific scientific and technical tests
77 or analytical services with respect to health products.
78
- 79 B. **Authorization** refers to the permission embodied in a document granted by the FDA
80 to a natural or juridical person who has submitted an application to implement the
81 manufacture, importation, exportation, sale, offer for sale, distribution transfer, and or
82 where appropriate, the use, testing, promotion, advertising, or sponsorship of health
83 products. The authorization can take the form of a permit, a license, a certificate of
84 registration, of accreditation, of compliance, or of exemption or any similar document.
85
- 86 C. **Center** refers to any of the following: Center for Cosmetics and Household/Urban
87 Hazardous Substances Regulation and Research (CCHUHSRR), Center for Food
88 Regulation and Research (CFRR), Center for Drug Regulation and Research (CDRR)
89 and Center for Device Regulation, Radiation Health and Research (CDRRHR) of the
90 FDA.
91
- 92 D. **Establishment** refers to the sole proprietorship, a partnership, a corporation an
93 institution, an association or an organization engaged in the manufacture, importation,
94 exportation, sale, offer for sale, distribution, donation transfer, use, testing, promotion,

95 advertising, or sponsorship of health products, including the facilities and installation
96 needed for its activities.

97
98 E. **Evaluation** refers to the process of reviewing submitted regulatory documents by
99 applicants based on existing standards, rules, and regulations of the FDA.

100
101 F. **Health Products** refers to food, drugs, cosmetics, devices, biologicals, vaccines, in-
102 vitro diagnostic reagents, and household/urban hazardous substances and/or a
103 combination of and/or a derivative thereof. It shall also refer to products that may have
104 an effect on health which require regulations as determined by the FDA.

105
106 G. **Health Product Vigilance** refers to the science and activities relating to the detection,
107 assessment, understanding, and prevention of adverse effects or any other possible
108 problems from Health Products.

109
110 H. **Initial application** refers to the term used for a first-time or original application for any
111 authorization as defined by RA No. 9711.

112
113 I. **Micro Small Medium Enterprises (MSMEs)** refers to the definition according to
114 Republic Act No. 9501 as any business activity or enterprise engaged in industry,
115 agribusiness and/or services, whether single proprietorship, cooperative, partnership or
116 corporation whose total assets, inclusive of those arising from loans but exclusive of the
117 land on which the particular business entity's office, plant and equipment are situated,
118 must have value falling under the following categories: a.) Micro, not more than
119 P3,000,000, b.) Small, P3,000,001 but not more than P15,000,000, and c.) Medium,
120 P15,000,001 but not more than P100,000,000. More than P100,000,000 is considered a
121 large enterprise.

122
123 J. **Re-issuance** refers to the process of granting a duplicate copy of a valid authorization
124 due to loss or damage of the original authorization. This is only applicable when the
125 document issued by the FDA is a hard copy and not an electronic copy.

126
127 K. **Renewal** refers to the process of filing an application for the extension of the validity
128 of an authorization.

129
130 L. **Risk-based Regulation** refers to the approach on regulating health products,
131 establishments, and facilities by targeting activities that pose the highest risk to the
132 public well-being, and in turn lowers the burden for a variety of lower-risk sectors and
133 firms. Lowering burdens improves compliance and allows firms to benefit from a more
134 level playing field. By directing the government resources towards the highest-risk
135 areas, risk-based approaches also make the most of limited public resources and
136 further improve accountability by enhancing transparency and predictability of
137 requirements in given sectors and as applied to different establishments.

138
139 M. **Variation and/or Amendment** refers to post-license changes in the status,
140 circumstances, conditions, claims, or activities of authorized establishments, in
141 accordance with existing guidelines.

144 **V. GUIDELINES**

145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191

- A. The new schedule of fees and charges is attached as Annexes A to F, as follows:
 - 1. Annex A for Fees on General Certification (Common to all Centers)
 - 2. Annex B for Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR)
 - 3. Annex C for Center for Drug Regulation and Research (CDRR)
 - 4. Annex D for Center for Device Regulation Radiation Health and Research (CDRRHR)
 - 5. Annex E for Center for Food Regulation and Research (CFRR)
 - 6. Annex F for Common Services Laboratory (CSL)

- B. The application fees for granting an authorization/accreditation prescribed in this issuance shall cover but is not limited to the following activities :
 - 1. Receiving of application documents;
 - 2. Pre and Post Licensing Inspection of facilities for medical device;
 - 3. Pre-marketing activities, including but not limited to assessment, technical evaluation and pre-licensing inspection of establishment;
 - 4. Post-marketing surveillance of products and establishments, but not limited to the following:
 - a. Collection of samples;
 - b. Laboratory testing;
 - c. Complaints and reports processing;
 - d. Safety monitoring;
 - e. Post-licensing inspection;
 - f. Routine/special inspection;
 - g. Health Product Vigilance
 - h. Post evaluation;
 - i. Product verification;
 - j. Advertisement monitoring;
 - 5. Printing;
 - 6. Records management, archiving and administrative support;
 - 7. Government Courier services to deliver the authorization, if applicable;
 - 8. IT systems, maintenance, and development;
 - 9. Security Seal; and
 - 10. And all other related activities

- C. The application fees shall not cover the following expenses:
 - 1. UP Law Center’s Legal Research Fee (LRF) which is equivalent to P10.00 or 1% of the application fee, whichever is higher, as imposed by Republic Act (RA) No. 3870, as amended by Presidential Decree (PD) No. 200 and further amended by PD 1856, of which FDA is only the collecting agent as per Letter of Instruction No. 1182 dated 16 December 1981.
 - 2. Other fees incurred from the use of payment collection facilities, such as service fees charged by banks authorized by the FDA to collect its fees.
 - 3. Private/ Special Courier used for the conveyance of the certifications.

192 D. The FDA shall issue updated guidelines regarding new payment modes and methods
193 as necessary.

- 194 1. Through Over-the-Counter at Landbank of the Philippines (LBP) using the
195 LBP Oncoll Payment Slip;
- 196 2. Through Online LBP Link.BizPortal; or
- 197 3. Through Online Bills payment (Bancnet)
- 198 4. Other payment channels as may be determined by the FDA.
199

200 E. All payments shall be made not later than the date reflected in the Order of Payment
201 (OP). Payments beyond the validity of the OP shall be automatically forfeited.
202

203 F. Application payments made including but not limited to the following, shall not be
204 accepted and posted in the system:
205

- 206 1. Application payment with incomplete/insufficient amount paid;
- 207 2. Application payment with an incorrect reference number provided;
- 208 3. Application payment made through an unauthorized payment channel;
- 209 4. Application payment made beyond the validity of the issued FDA Order of
210 Payment; and
- 211 5. Such other cases as determined by the FDA.
212

213 Applications with deficiency payment shall be posted after the proof of the full
214 payment is made.
215

216 G. Changes and/or additions to the existing FDA payment channels shall be announced
217 through a separate issuance.
218

219 H. The size of business operation used by CCHUHSRR and CFRR for licensing
220 purposes (by asset) shall be in accordance with RA No. 9501 and its amendments.
221

222 I. Provision of support and assistance to MSMEs may be provided under the
223 coordination of government efforts stipulated in RA No. 9501 Section 5c and its
224 future amendments. Future related provisions will be carried out.
225

226 J. Flexibility in payment of fees and charges may be applied by the FDA in lieu of a
227 Public Emergency or State of Calamity declaration and other directives from the
228 Office of the President.
229

230 **VI. VALIDITY**

231 The validity period for authorizations, permits, and certificates shall follow existing
232 FDA issuances.
233

234 **VII. SURCHARGE OR PENALTY**

235 Consistent with R.A. No. 9711 and its IRR and other relevant FDA regulations, the
236 conditions for the imposition of surcharge or penalty are provided below as follows:
237
238
239
240

241
242 A. Pursuant to Section 3, Paragraph (A) (2) and (B) (2) of Article 1, Book II on
243 Licensing of Establishments and Registration of Health Products of IRR of RA 9711,
244 applicable surcharge or penalty shall be imposed for applications for renewal of
245 LTO or CPR received after the date of their expiration. This rule shall apply even in
246 succeeding renewal applications.

247
248 B. An application for renewal of an LTO or CPR received after its date of expiration
249 shall be subject to a surcharge or penalty equivalent to twice the renewal licensing fee
250 and an additional 10% per month or a fraction thereof of continuing non-submission of
251 such application within the maximum of one hundred twenty (120) days from its
252 original expiry date.

253
254 C. The LTO or CPR shall be considered valid and existing until a decision or resolution
255 by the FDA is rendered on the application for renewal.

256
257 D. LTO or CPR applications filed beyond the 120-day period shall be considered
258 expired and the application shall be subject to a fee equivalent to the total surcharge or
259 penalty plus the initial filing fee and the application shall undergo the corresponding
260 filing and evaluation procedure.

261 262 263 **VIII. MANDATORY REVIEW**

264
265 The fees and charges shall be subject to mandatory review every three (3) years. The
266 Policy and Planning Service shall undertake periodic review, conduct consultations with
267 stakeholders, and recommend amendments to this Administrative Order to the Office of the
268 Director-General for approval of the Secretary of Health, as may be deemed necessary.
269

270 271 **IX. REPEALING CLAUSE**

272
273 This Administrative Order effectively repeals the following issuances:

274
275 A. Administrative Order No. 50 s. 2001 entitled “Revised 2001 Schedule of Fees and
276 Charges for the Corresponding Services Rendered by the Bureau of Food and
277 Drugs”;

278
279 B. A.O. No. 18-A s. 1993 entitled “Standards of Quality and Requirements for the
280 Processing, Packaging and Labelling of Bottled Drinking Water”;

281
282 C. A.O. No. 15-A s. 1995 entitled “Guidelines Governing the Implementation of the
283 Sangkap Pinoy Seal (SPS) Program and the Collection and Disbursement of Fees
284 Generated from the Program”;

285
286 D. A.O. No. 29, s.2000 entitled “Amendment to AO No. 23 s 1999 and AO No. 50,
287 s.1999 Fees and Charges to be Collected by the Radiation Health Service”;
288

- 289 E. Article III Section 2 of DTI-DOH Joint Administrative Order No. 01 s. 2000,
290 entitled “Prescribing a Schedule of Fees and Charges for Sales Promotion
291 Activities”;
- 292
- 293 F. DOH A.O. No. 47A s 2001 entitled “Rules and Regulations on the Registration,
294 Including Approval and Conduct of Clinical Trials, and Lot or Batch Release
295 Certification of Vaccines and Biologic Products”;
- 296
- 297 G. A.O. NO. 82 s. 2003 entitled “Guidelines on the Granting of Diamond Sangkap
298 Pinoy Seal to Manufacturers of Fortified Products”;
- 299
- 300 H. A.O. No. 2008-0033 entitled “Rules and Conditions in Exempting Antibiotic Drug
301 Products from Batch Certification Requirement Amending for this purpose Item III
302 (C) and (D) of AO No. 103 s. 2002 “Batch Certification of Antibiotics” and for
303 Other Purposes”;
- 304
- 305 I. A.O. No. 2012-0024 entitled “Amendment to A.O. No. 50 s. 2001 Covering Fees
306 and Charges for Accreditation of Bioequivalence Testing Centers and Private
307 Testing Laboratories, as well as, Audits and Inspection”;
- 308
- 309 J. FDA Circular No. 2011-004 entitled “Computation of Surcharge or Penalty
310 Imposable in case of Submission of Renewal Applications Covering License of
311 Establishments and Registration of Health Products *After* Their Date of Expiration
312 Pursuant to Section 3, Paragraphs (A)(2) and (B)(2) of Article I of Book II of the
313 RA 9711 Implementing Rules and Regulations, and Other Purposes”;
- 314
- 315 K. DOH Administrative Order No. 2019-0010 entitled “Guidelines on the Regulation
316 of Operators of Pest Control, Certification of Pesticide Handlers, and Accreditation
317 of Their Training Providers”, Annex E, specifically the Schedule of Fees for the
318 "License to Operate for Pest Control Operators";
- 319
- 320 L. FDA Circular No. 2013-001-A entitled “Amendment of FDA Circular No. 2013-
321 001”;
- 322
- 323 M. FDA Circular No. 2023-003 entitled “Guidelines on the Filing and Submission of
324 Acceptable Variations on Protocols and Non-standard Protocols for the Review and
325 Pre-Approval by the Food and Drug Administration Prior to the Conduct of Bio-
326 efficacy Test Studies of Household Pesticides for the Purposes of Securing a
327 Certificate of Product Registration”;
- 328
- 329 N. FDA Circular No. 2015-001 entitled “Clarifications on the Regulations Governing
330 Principal and Identical Drug Products as defined under Administrative Order No.
331 2005-0031”.
- 332
- 333
- 334
- 335
- 336
- 337

338 **X. SEPARABILITY CLAUSE**

339

340 If any provision is declared unauthorized or rendered invalid by any court of law or
341 competent authority, those provisions not affected thereby shall remain valid and effective.

342

343

344 **XI. EFFECTIVITY DATE**

345

346 This Order shall take effect fifteen (15) days after its publication in the Official
347 Gazette or in any newspaper of general circulation and upon filing with the University of the
348 Philippines Law Center Office of the National Administrative Register.

349

350

351

352

353

354

355

TEODORO J. HERBOSA, MD
Secretary of Health

356

Food and Drug Administration	Food and Drug Administration
IRENE F. FLORENTINO-FARIÑAS, RPh, MD, MNSA OIC Director III, Policy and Planning Service	SAMUEL A. ZACATE, MD Director General

357

358

Keywords	
Related Issuances, laws, directives from other government agencies	Administrative Order No. 50 s. 2001 "Revised 2001 Schedule of Fees and Charges for the Corresponding Services Rendered by the Bureau of Food and Drugs"

359

360